Plga Nanoparticle Formulation of Rk-33: an Rna Helicase Inhibitor Against Ddx3
Cancer chemotherapy and pharmacology(2015)
摘要
The DDX3 helicase inhibitor RK-33 is a newly developed anticancer agent that showed promising results in preclinical research (Bol et al. EMBO Mol Med, 7(5):648–649, 2015). However, due to the physicochemical and pharmacological characteristics of RK-33, we initiated development of alternative formulations of RK-33 by preparing sustained release nanoparticles that can be administered intravenously.
更多查看译文
关键词
DDX3,PLGA,RK-33,Nanoparticles,Drug release
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要